TOKYO, 10 Feb. 08, 2022 (GLOBE NEWSWIRE) — FUJIFILM Corporation (President and Chief Executive Officer, Representative Director: Teiichi Goto) announces the launch of its life sciences strategic investment fund managed by Life Sciences Corporate Venture Capital (LS-CVC ), a newly established group within Fujifilm’s Life Sciences Strategy Headquarters in Tokyo. Fujifilm is initially investing 7 billion JPY (about 60 million USD  ) to start the fund, targeting cutting-edge biotechnology primarily through partnerships with start-up companies around the world.
In addition to this new fund, the LS-CVC also supports the company’s portfolio of previous life science investments, which had already been made in the fields of regenerative medicine, cell therapy and research products for drug discovery. Fujifilm envisions a wide range of new and innovative business constructions to cultivate and foster relationships with emerging biotechs to create new businesses and strengthen existing businesses.
In April 2021, Fujifilm established the Life Science Strategy Headquarters to plan and promote a comprehensive and integrated strategy to accelerate the growth of life science businesses. The headquarters currently manages several business divisions in the areas of biopharmaceutical contract development and manufacturing, iPS cell-derived products for the drug research and discovery markets, and industrial cell culture media. The Life Sciences Strategy Headquarters will direct the placement of this fund taking into account the strategic business alignment and development timeline of the Life Sciences Divisions.
As part of the Life Sciences Strategy Headquarters, FUJIFILM’s Life Sciences Strategic Business Offices in the United States (Cambridge) and Europe (Düsseldorf) will take on the important role of approaching biotech start-ups that possess advanced biotechnologies and know-how. how, and will develop funding arrangements for the partnership with Fujifilm.
“In the field of life sciences, research and development of new technologies and the application of biotechnologies have been accelerated to provide solutions to unmet medical needs and other societal problems, such as food problems and environmental,” said Takatoshi Ishikawa, CEO of Life Sciences. Strategy Headquarters. “In many cases, start-ups are the first to develop breakthrough technologies and innovative business models. I believe that LS-CVC’s activities will allow us to quickly develop new partnerships with such promising companies and bring value to society through innovative products.
 At the exchange rate of 1 USD = 116.305 JPY on February 10, 2022.
Christine Jackman FUJIFILM Holdings America Corporation 9142614959 [email protected]
Copyright 2022 GlobeNewswire, Inc.